Associazione Nazionale Medici Cardiologi Ospedalieri

www.anmco.it

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
“Finding of myocardial crypts in sudden cardiac arrest patients: two case report”
Anno:
2023
Left ventricular myocardial crypts are definined as deep blood-filled invaginations trasversing > 50% of the myocardial wall and are located predominantly at the mid-basal segment of inferoseptal wall or at the apical segment. To date the incidence of crypts is 9.1% of patients undergoing cardiac CT and are not…
Leggi di più
A New Magnetic Resonance Imaging Technique to Assess Prognosis in Patients With Hypertrophic Cardiomyopathy and Low-Intermediate 5-Year Risk of Sudden Death
Anno:
2023
BACKGROUND: Late gadolinium enhancement (LGE) is an important prognostic marker in hypertrophic cardiomyopathy and an extent >15% it is associated with high risk of sudden cardiac death. We proposed a novel method, the LGE-dispersion mapping, to assess heterogeneity of scar, and evaluated its prognostic role in patients with hypertrophic…
Leggi di più
ROLE OF RESTRICTIVE DIASTOLIC DYSFUNCTION FOR RISK STRATIFICATION OF PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY: A BAYESIAN MODEL AVERAGING
Anno:
2023
BACKGROUND Hypertrophic cardiomyopathy (HCM) is characterized by increased left ventricular (LV) stiffness, leading to raised ventricular filling pressures and restrictive diastolic dysfunction (RDD), in itself independently associated with an increased risk of a clinical deterioration. We assessed whether echocardiography evaluation of diastolic function in HCM could yield prognostic value…
Leggi di più
LVOTO IN HCM: HYBRID TREATMENT MAY STILL NOT SOLVE CHALLENGING CASES
Anno:
2023
MA, a 28 years old male with a diagnosis of OHCM since 2008, came to our attention for effort dyspnea (NYHA II) and fatigue limiting his greengrocer activity. Decompensated T1DM (HbA1C 12%), HTN, obesity (BMI 37). In 2017 he implanted a bicameral ICD in primary prevention, later extracted for…
Leggi di più
Genetic cardiomyopathies: the first year of the Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico of Milan dedicated clinical service
Anno:
2023
Objectives: Cardiac genetic counselling and testing for inherited cardiomyopathies have become essential aspects of  cardiovascular care. A genetic diagnosis in a family can offer an invaluable tool for cascade genetic testing of at-risk relatives. A careful clinical and individualized approach to genetic cardiomyopathies is now needed to guarantee the best care possible. We report the results of our…
Leggi di più
Transcatheter ablation of supraventricular arrhythmias in patients suffering from hypertrophic cardiomyopathy: a propensity score-based analysis
Anno:
2023
BACKGROUND To date, the prognostic impact of transcatheter ablation (T-Abl) of supraventricular arrhythmias (SA) in HCM patients has not been satisfactorily elucidated.   OBJECTIVES To assess the impact of T-Abl on clinical outcomes in a large cohort of HCM patients.   METHODS In this retrospective multicenter study, 570 consecutive…
Leggi di più
CONTRAST-ENHANCED ECHOCARDIOGRAPHY IN BETTER STUDYING (OR EXCLUDING) HYPERTROPHIC CARDIOMYOPATHY. TWO CASES.
Anno:
2023
Aim of this case-series report is to elucidate the potential role of contrast echocardiography (C-Echo) to optimize and improve the study of patients with Hypertrophic Cardiomyopathy (HCM). However, this report is also aimed to demonstrate the role of C-Echo in excluding a HCM diagnosis.   Case 1. A young…
Leggi di più
FATAL CONSPIRACY: MIDVENTRICULAR OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY COMPLICATED BY GIANT APICAL ANEURYSM AND SEVERE MITRAL REGURGITATION
Anno:
2023
This case refers to a 69-year-old woman with a history of hypertrophic cardiomyopathy (HCM) with severe mid-ventricular obstruction complicated by apical aneurysm and restrictive phenotype. This patient had no left ventricular outflow tract obstruction and previous examinations showed moderate mitral regurgitation (MR) with suboptimal echocardiographic follow-up. ICD was previously…
Leggi di più
MARCHE REGIONAL NETWORK FOR CARDIAC AMYLOIDOSIS AND HYPERTOPHIC CARDIOMYOPATHY: INSIGHTS FROM 3-YEAR COLLABORATIVE EXPERIENCE.
Anno:
2023
Background and Methods: the management of patients with Cardiac Amyloidosis (CA) and Hypertrophic Cardiomyopathy (HCM) is complex and requires specific skills. Collaboration between centres remains essential because not all centres can perform complex diagnostic techniques (such as endomyocardial biopsy and mass spectrometry) or prescribe disease-modifying therapies, Therefore, in 2019 we created a…
Leggi di più

A.N.M.C.O. – Via La Marmora 36, 50121 Firenze (Italy) – Partita I.V.A. 05469530488 – Codice Fiscale 01301130488 – Privacy
www.anmco.it | segreteria@anmco.it

Seguici su

Facebook Twitter Youtube Linkedin Instagram Telegram